AHR and neoplasm: In particular, inhibitors of IDO1 and TDO2 were revealed as potential anticancer immunomodulators.489–491 The IDO1/TDO2-dependent immunosuppressive effects are mediated through the formation of the endogenous AHR agonist kynurenine, which targets tumor-infiltrating T cells.